EPS: As of FY2025 Q1, the actual value is USD -0.32.<h3>Segment Revenue</h3><ul><li>The company did not generate any revenue for the three months ended March 31, 2025, and March 31, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $1,017,092 for the three months ended March 31, 2025, compared to a net loss of $865,970 for the same period in 2024, representing a 17.45% increase.</li><li>Operating Expenses: Total operating expenses increased by 14.94% from $903,536 in 2024 to $1,038,486 in 2025.</li><li>Research and Development: Expenses increased by 72.45% from $245,625 in 2024 to $423,576 in 2025.</li><li>General and Administrative: Expenses decreased by 6.54% from $657,911 in 2024 to $614,910 in 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: The company used $926,125 in operating activities for the three months ended March 31, 2025, compared to $1,303,411 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: Cash provided by financing activities was $347,549 for the three months ended March 31, 2025, primarily from the ATM Offering.</li></ul><h3>Unique Metrics</h3><ul><li>Warrant Liability: The fair value of the warrant liability decreased from $4,670 at December 31, 2024, to $3,315 at March 31, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue substantial investment in development activities for NELL-1 as it prepares for a pivotal clinical study.</li><li>Non-Core Business: The company intends to seek stockholder approval for a reverse stock split to regain compliance with Nasdaq’s listing requirements.</li><li>Priority: The company is focused on raising additional debt and/or equity financing to fund future operations and provide additional working capital.</li></ul>

BONE BIOLOGICS CORP C/WTS 13/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.32